March 9, 2021
Business News

Why Investors Should Buy Moderna Stock

Moderna (NASDAQ:MRNA) has arguably priced in the medium-term proceeds from its vaccine for the novel coronavirus. But Moderna stock does not yet appear to reflect the potential of its other vaccines under development, the promising drugs it can acquire in the future, or its own status as a potential takeover target.

The Moderna (MRNA) logo surrounded by syringes, pills and disposable face masks.Source: Ascannio / Shutterstock.com

Of course Moderna’s vaccine, MRNA-1273, recently won emergency-use approval (EUA) from the FDA. Moreover, Moderna’s vaccine generated excellent efficacy…

Click here to view the original article.

Related Posts

You might also like ...

Concordium Raises $15M in Private Sale and Completes MVP Testnet
Synthace Appoints Dr. Nick Jurascheck as VP of Engineering
Avacta Signs Diagnostic Licensing Deal with Biokit